News - Genentech

Filter

Current filters:

Genentech

Popular Filters

26 to 50 of 58 results

US biotech giants lobbying to block biosimilars, NTY claims

31-01-2013

Some of the USA's biggest biotechnology companies are lobbying intensively to limit generic competition…

AmgenBiotechnologyGenentechGenericsNorth AmericaPoliticsRegulation

FDA clears new use for Roche's Avastin and Novartis' Exjade

25-01-2013

The US Food and Drug Administration has approved a new use for Swiss drug major Roche's (ROG: SIX) US…

AvastinBiotechnologyExjadeGenentechNorth AmericaNovartisOncologyPharmaceuticalRegulationRoche

San Antonio breast cancer meeting highlights

10-12-2012

There was mixed news coming out of the San Antonio Breast Cancer Symposium (SABCS), which concluded on…

AvastinBiotechnologyEisaiGenentechHerceptinOncologyPerjetaPharmaceuticalResearchRoche

Curis in-licenses cancer candidate from Genentech

30-11-2012

US drug development firm Curis (Nasdaq: CRIS) that it has licensed from Genentech, a subsidiary of Swiss…

BiotechnologyCurisGDC-0917GenentechGUDC-427LicensingOncologyPharmaceuticalRoche

FDA Approves Abraxane for NSCLC and expands indication for Actemra

15-10-2012

The US Food and Drug Administration on Friday approved biotech firm Celgene's (Nasdaq: CELG) Abraxane…

AbraxaneActemraAnti-Arthritics/RheumaticsBiotechnologyCelgeneGenentechNorth AmericaOncologyPharmaceuticalRegulationRoche

US oncologists' perceptions of Roche's Perjeta very promising

07-09-2012

Swiss drug major Roche (ROG: SIX) and subsidiary Genentech's Perjeta (pertuzumab), which has been available…

afatinibAfinitorBiotechnologyGenentechMarkets & MarketingNorth AmericaOncologyPerjetaPharmaceuticalRoche

Genentech's T-DM1 significantly improved survival for metastatic breast cancer patients

29-08-2012

Swiss drug major Roche (ROG: SIX) US subsidiary Genentech has announced updated results from the Phase…

BiotechnologyGenentechOncologyPharmaceuticalRegulationResearchRocheT-DM1trastuzumab emtansine

Roche gains FDA approval for Lucentis in diabetic macular edema

13-08-2012

US biotech firm Genentech, a subsidiary of Swiss drug major Roche (ROG: SIX) announced on Friday that…

GenentechLucentisNorth AmericaOphthalmicsPharmaceuticalRegulationRoche

Genentech gains FDA panel backing for Lucentis to treat DME

30-07-2012

US biotech firm Genentech, a subsidiary of Swiss drug major Roche (ROG: SIX), revealed last week that…

BiotechnologyGenentechLucentisNorth AmericaOphthalmicsPharmaceuticalRegulationRoche

Second collaboration in Alzheimer's disease for Genentech and AC Immune

18-06-2012

Switzerland-based biopharma company AC Immune said this morning that it has entered into a second exclusive…

AC ImmuneBiotechnologycrenezumabGenentechLicensingNeurologicalPharmaceuticalResearchRoche

FDA backs Roche's personalized breast cancer therapy Perjeta

11-06-2012

The US Food and Drug Administration on Friday approved Swiss drug major Roche (ROG: SIX) subsidiary Genentech's…

BiotechnologyGenentechNorth AmericaOncologyPerjetapertuzumabPharmaceuticalRegulationRoche

ASCO 2012: "Show me the overall survival data," say analysts

07-06-2012

The annual American Society of Clinical Oncology (ASCO) meeting, held this year in Chicago from June…

GenentechJohnson & JohnsonOncologyPharmaceuticalResearchRochetrastuzumab emtansineZytiga

Genentech links up with Ensemble Thera for macrocyclic drug candidates discovery

30-05-2012

Swiss drug major Roche's (ROG: SIX) subsidiary Genentech has initiated a drug discovery collaboration…

BiotechnologyEnsemble TherapeuticsGenentechLicensingResearchRoche

Groundbreaking Alzheimer's prevention trial announced, as US debuts AD program

17-05-2012

A collaboration of the US National Institutes of Health (NIH), Banner Alzheimer's Institute (BAI), University…

crenezumabGenentechNeurologicalNorth AmericaPharmaceuticalPoliticsResearchRoche

US retinal therapeutics market buoyant, says F&S

07-05-2012

Alarm bells are ringing loud and clear as diabetes has grown to epidemic proportions worldwide, triggering…

AvastinGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRoche

Roche to file for trastuzumab emtansine this year, on positive Ph III results

03-04-2012

Swiss drug major Roche (ROG: SIX) says that top-line results of EMILIA, the first randomized Phase III…

BiotechnologyGenentechGlaxoSmithKlineOncologyPharmaceuticalRegulationResearchRochetrastuzumab

GSK settles with Genentech over ofatumumab patents

28-03-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) has agreed a settlement with Genentech, a unit of Roche (ROG:…

ArzerraBiotechnologyGenentechGenmabGlaxoSmithKlineLegalOfatumumab InjectionOncologyPatentsPharmaceuticalRoche

Counterfeit Avastin found in USA by FDA

16-02-2012

The US Food and Drug Administration said yesterday that it is warning health care professionals and patients…

AvastinGenentechMarkets & MarketingNorth AmericaOncologyPharmaceuticalRegulationRoche

Faster-than-expected FDA approval of Roche’s vismodegib

31-01-2012

There was good news for Swiss drug major Roche's (ROG: SIX)subsidiary Genentech yesterday, when it received…

BiotechnologyCurisErivedgeGenentechNorth AmericaOncologyPharmaceuticalRegulationRochevismodegib

Roche in epigenetics drug discovery collaboration

18-01-2012

USA-based Constellation Pharmaceuticals says that it has entered into a major strategic agreement with…

BiotechnologyConstellation PharmaceuticalsGenentechLicensingMergers & AcquisitionsOncologyPharmaceuticalRoche

Xenon in $646 million deal with Roche unit

10-01-2012

Canada based Xenon Pharmaceuticals, a privately-owned, clinical genetics-based drug discovery and development…

BiotechnologyGenentechLicensingNeurologicalPharmaceuticalResearchRocheXenon Pharmaceuticals

Vernalis jumps on deal with Genentech

05-01-2012

The UK's Vernalis (LSE: VER) saw its shares jump more than 5% to 20.75 yesterday, after the company revealed…

FinancialGenentechIpsenLicensingLundbeckPharmaceuticalRocheVernalis

26 to 50 of 58 results

Back to top